Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axim Biotechnologies Inc (OP: AXIM )

0.0103 -0.0006 (-5.50%)
Streaming Delayed Price Updated: 3:36 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 880,241
Open 0.0106
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0109
Today's Range 0.0099 - 0.0119
52wk Range 0.0090 - 0.0399
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024
Company CEO John Huemoeller II Interviewed by Tony Noto on AXIM’s Diagnostic Research Programs in Dry Eye Disease and Parkinson’s 
Via TheNewswire.com
VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire

Performance

YTD
-49.51%
-49.51%
1 Month
-20.16%
-20.16%
3 Month
-46.63%
-46.63%
6 Month
-47.18%
-47.18%
1 Year
-61.42%
-61.42%

More News

Read More
AXIM Biotechnologies Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation
Via NewMediaWire
AXIM Biotechnologies Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation
Via TheNewswire.com
AXIM Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production
Via NewMediaWire
AXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson’s Disease
From AXIM Biotechnologies, Inc.
Via Business Wire
AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test
From AXIM Biotechnologies, Inc.
Via Business Wire
Update: AXIM Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
Via NewMediaWire
AXIM Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
Via NewMediaWire
AXIM Biotechnologies Announces Over 40 Initial Clinic Commitments for Its Full Diagnostic Assay Platform Launch
Via NewMediaWire
AXIM Biotechnologies Appoints Kurt Phinney as Chief Operating Officer to Drive Scaling and Optimization of Manufacturing Unit
Via NewMediaWire
Exposures Product Safety
AXIM Biotechnologies Commences Commercial Manufacturing of FDA-Cleared Proprietary Ocular Diagnostic Assays
Via NewMediaWire
AXIM Biotechnologies Files Provisional Patent on Novel Methodology for Use in Optical Diagnostic Assay Manufacturing
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
Medical Marijuana, Inc. Appoints New CEO; Highlights Renewed Focus on Profitability, Further Expansion
Via NewMediaWire
Topics Cannabis
Exposures Cannabis
AXIM Biotechnologies Files Patent on Fentanyl Neutralizing Antibody Test, Applies for DEA License to Work With Controlled Substance
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
AXIM® Biotechnologies Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test; Files Provisional Patent
From AXIM BIOTECHNOLOGIES, INC
Via GlobeNewswire
AXIM Biotechnologies Commercial Partner Verséa Ophthalmics Highlights Benefits of AXIM’s Eye Diagnostic Solutions
From AXIM BIOTECHNOLOGIES, INC
Via GlobeNewswire
AXIM® Biotechnologies Receives Initial Order for Diagnostic Solutions as Exclusive Partner Verséa Ophthalmics Commences Initial Commercial Launch
From AXIM BIOTECHNOLOGIES, INC
Via GlobeNewswire
AXIM® Biotechnologies Point-of-Care Diagnostic Test Platform Sales Commence With Verséa Ophthalmics’ Commercial Launch at AAO 2022
From AXIM BIOTECHNOLOGIES, INC
Via GlobeNewswire
AXIM Biotechnologies Enhances IgE Testing Capabilities; Responds to Global Warming's Impact on Allergy Season
From AXIM BIOTECHNOLOGIES, INC
Via GlobeNewswire
Will This Dry Eye Rapid Test Prove To Be A Rapid Success?
Via Benzinga
Medical Marijuana, Inc. Reports Revenue Of $7.8M For Q1 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.